Mahomed Salame, MD
Cardiovascular Disease · Anniston, ALNPI 1487625661
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $55,248 of the $58,925 with a category attached, or 93.8%. Medtronic accounts for 94.1% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $56,022 and has fallen 99.1% since, to $523 in 2025. Among cardiovascular disease clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $261.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$55K
- Johnson & Johnson$628
- E.r. Squibb & Sons, L.L.C.$510
- Pfizer$411
- Abbott$312
- Cardiva Medical, Inc.$250
- plus $1K from 21 others
Across 2 payments — averaging $552,853 each. An ownership or investment interest held by the physician or an immediate family member.
- Corvista Health, Inc.$1.1M
What the payments were for
- Royalty or licence$55,24894%
- Food & beverage$3,6446%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(3 entities) | 22 | $55,455 |
| Johnson & Johnson(2 entities) | 42 | $628 |
| E.r. Squibb & Sons, L.L.C. | 31 | $510 |
| Pfizer | 26 | $411 |
| Abbott | 17 | $312 |
| Cardiva Medical, Inc. | 14 | $250 |
| Amgen | 10 | $168 |
| Novartis | 9 | $157 |
| Boston Scientific | 6 | $129 |
| Irhythm Technologies, Inc. | 6 | $124 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $119 |
| Merck | 7 | $119 |
| Biotronik Inc. | 4 | $102 |
| Novo Nordisk | 4 | $94 |
| AstraZeneca | 6 | $84 |
| Actelion Pharmaceuticals US, Inc. | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Bard Peripheral Vascular, Inc. | 1 | $30 |
| Shockwave Medical, Inc | 1 | $29 |
| Elutia, Inc. | 1 | $25 |
| Impulse Dynamics (USA) Inc. | 1 | $21 |
| Biogen | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Cvrx, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$55,248
How this compares
$58,925 in reported general payments places this provider in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,053 | $1,124,121 |
| XareltoRivaroxaban | 212 | $185,133 |
| BrilintaTicagrelor | 159 | $118,015 |
| EntrestoSacubitril/Valsartan | 95 | $108,665 |
| Ranolazine ErRanolazine | 208 | $20,572 |
| JardianceEmpagliflozin | 19 | $10,936 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 483 | $8,291 |
| Atorvastatin Calcium | 554 | $7,393 |
| ClopidogrelClopidogrel Bisulfate | 554 | $7,349 |
| Metoprolol Succinate | 411 | $7,171 |
| Diltiazem 12hr ErDiltiazem Hcl | 23 | $6,887 |
| Amlodipine Besylate | 944 | $6,471 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 148 | $6,398 |
| Losartan Potassium | 488 | $6,385 |
| Carvedilol | 540 | $5,455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $411 | $1,124,1211,053 claims |
| Johnson & JohnsonXarelto | $628 | $185,133212 claims |
| AstraZenecaBrilinta | $84 | $118,015159 claims |
| NovartisEntresto | $157 | $108,66595 claims |
| Boehringer IngelheimJardiance | $14 | $10,93619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Anniston
- Dennis ThomasMobile$894K
- David FienoAlabaster$421K
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Ajit NaiduFlorence$66K
- Thomas CawthonBirmingham$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.